Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Difluoromethylornithine (DFMO) Post-Immunotherapy for High-Risk Neuroblastoma (HRNB): DFMO improved event-free survival (EFS) and overall survival (OS) in HRNB patients post-immunotherapy compared to a control group; EFS (hazard ratio (HR), 0.50 [95% confidence interval (CI), 0.29 to 0.84]; P = .008) and OS (HR, 0.38 [95% CI, 0.19 to 0.76]; P = .007).
• Dinutuximab Immunotherapy for HRNB: Patients in the dinutuximab immunotherapy group showed higher 5-year survival outcomes than those in the isotretinoin-only group, with a 5-year EFS of 56.6 ± 4.7% vs. 46.1 ± 5.1% (P = 0.042) and a 5-year OS of 73.2 ± 4.2% vs. 56.6 ± 5.1% (P = 0.045).
• Effectiveness Summary: Both DFMO and dinutuximab demonstrated significant improvements in EFS and OS for HRNB patients, with DFMO showing HRs of 0.50 for EFS and 0.38 for OS, and dinutuximab showing a 10.5% higher 5-year EFS and 16.6% higher 5-year OS compared to isotretinoin-only treatment.
• There is no safety information available in the reviewed studies for DFMO. For dinutuximab, 13 out of 122 patients developed human anti-chimeric antibodies (HACA), but these did not correlate with event-free or overall survival or with clinically significant toxicity; FC gamma receptor 2A and 3A genotypes similarly showed no correlation with survival or significant toxicity.
• There is no population types or subgroup information available in the reviewed studies.